A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Trial details
- Registry ID
- NCT05548296
- Phase
- Phase 2
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaNCT05548296 | Acrivon Therapeutics | Phase 2 | Recruiting | 2027-05-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |